Exabis Library
Welcome to the e-CCO Library!
P544: Impact of patient education on switch acceptance in IBD patients in remission, with infliximab originator switched for an infliximab biosimilar: a prospective study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P544: Low TNF production and low TREM1 expression as negative predictors for remission under adalimumab therapy in Crohn´s Disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P544: Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P544: Point-of-care finger prick test for C-reactive protein, infliximab and adalimumab serum concentrations
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P545 Deep remission assessed by endoscopy, magnetic resonance or intestinal ultrasound, in refractory Crohn’s disease patients in clinical remission with ustekinumab: a real-life single-centre experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P545: Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P545: Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with Vedolizumab
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P545: Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary results
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P545: Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P545: Elderly patients with inflammatory bowel disease (IBD) are less likely to persist on anti-TNF therapy compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P545: Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P546 Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P546: Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P546: Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P546: The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P546: Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P546: Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P546: Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P547 Inadequate vitamin C status and association with inflammatory biomarkers in adults with active Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P547: Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM